UCB Group, Roche and Celgene Corp. are backing UK life sciences by committing multi-million investments into research hubs in the country, providing a much-needed boost to the country’s morale, as it continues to implode over Brexit negotiations.
Brussels-headquartered pharma UCB is leading the charge, by investing £150-200m to build a new research facility in Slough, Berkshire. This...








